HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- ((2,2- dimethylchroman- 6- yl)sulfonyl)- N- (4- phenoxybenzyl)glycine

inhibits both sn-1-diacylglycerol lipase alpha and ABHD6 protein; structure in first source

Also Known As:

LEI-106

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - Glycine: 5151
    - N-((2,2-dimethylchroman-6-yl)sulfonyl)-N-(4-phenoxybenzyl)glycine: 1
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - N-((2,2-dimethylchroman-6-yl)sulfonyl)-N-(4-phenoxybenzyl)glycine: 1
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - N-((2,2-dimethylchroman-6-yl)sulfonyl)-N-(4-phenoxybenzyl)glycine: 1

Experts

1.	Allarà, Marco: 1 article (08/2014)
2.	Baggelaar, Marc P: 1 article (08/2014)
3.	Deng, Hui: 1 article (08/2014)
4.	Di Marzo, Vincenzo: 1 article (08/2014)
5.	Janssen, Freek J: 1 article (08/2014)
6.	Ligresti, Alessia: 1 article (08/2014)
7.	McGuire, Ross: 1 article (08/2014)
8.	Overkleeft, Herman S: 1 article (08/2014)
9.	den Dulk, Hans: 1 article (08/2014)
10.	van Esbroeck, Annelot C M: 1 article (08/2014)

Related Diseases

1.	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/14/2014 - "Finally, we identified LEI-106 as a potent, dual DAGL-α/ABHD6 inhibitor, which makes this compound a potential lead for the discovery of new molecular therapies for diet-induced obesity and metabolic syndrome. "
2.	Obesity 08/14/2014 - "Finally, we identified LEI-106 as a potent, dual DAGL-α/ABHD6 inhibitor, which makes this compound a potential lead for the discovery of new molecular therapies for diet-induced obesity and metabolic syndrome. "

Related Therapies and Procedures

1.	Therapeutics